Completed PHASE2 INTERVENTIONAL 4-arm NCT03538522

A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of NA-831 in Alzheimer Patients With Mild Cognitive Impairment

Sponsor: Biomed Industries, Inc.

Conditions Alzheimer Dementia Alzheimer Disease Cognitive Disorder Cognitive Impairment Dementia With Lewy Bodies Dementia, Vascular Mild Cognitive Impairment Neurocognitive Disorders Neurodegenerative Diseases Tauopathies

Interventions N-831(Traneurocin) 10 mg QD NA-831 (Traneurocin) 20 mg QD NA-831 (Traneurocin) 40 mg QD Placebo oral capsule QD

Updated 6 times since 2018 Last updated: Jun 26, 2020 Started: Sep 15, 2018 Primary completion: Sep 30, 2019 Completion: Oct 30, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Alzheimer Dementia and Alzheimer Disease, this trial is completed. The trial is conducted by Biomed Industries, Inc. and has accumulated 6 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jul 2020 — Jan 2021 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Jun 2020 — Jul 2020 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status

▶ Show 1 earlier version

Jun 2018 — Jun 2020 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biomed Industries, Inc.

Data source: Biomed Industries, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Auckland, New Zealand